Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia.

Area of Science:

• Hematology
• Oncology
• Surgical Oncology

Background:

• Chronic leukemias, including chronic lymphocytic leukemia (CLL) and chronic granulocytic leukemia (CGL), frequently cause significant morbidity due to splenic enlargement and hyperfunction.
• The indications for splenectomy in these conditions remain unclear, necessitating further investigation into patient selection for optimal outcomes.

Purpose of the Study:

• To identify patient subgroups with chronic leukemias who experience the most benefit from splenectomy.
• To evaluate the efficacy of splenectomy for palliation of massive splenic bulk and improvement of hematologic sequelae of splenic hyperfunction.

Main Methods:

• A retrospective study of 17 patients (9 with CLL, 8 with CGL) who underwent splenectomy.
• Patients were categorized based on the primary indication for surgery: palliation of splenic bulk symptoms or treatment of splenic hyperfunction.

Main Results:

• Splenectomy provided good palliation for splenic bulk symptoms, but the duration of benefit was disease-stage dependent. Five of eight CGL patients with bulk symptoms died within six months post-surgery.
• Splenectomy for splenic hyperfunction yielded only short-term hematologic responses. In Coombs-positive CLL patients, autoantibodies correlated with transfusion requirements within three months.

Conclusions:

• The benefits of splenectomy for splenic bulk must be weighed against surgical risks and patient prognosis. Splenectomy for splenic hyperfunction efficacy is contingent on the underlying cause and may not benefit patients with refractory autoimmune anemias.